Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
about
Influenza vaccination in HIV-positive subjects: latest evidence and future perspectiveInfluenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspectiveSeroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controlsHigher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohortVitamin D Levels, Natural H1N1 Infection and Response to H1N1 Vaccine among HIV-Infected IndividualsImmune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.The Comparison of Sensitivity and Specificity of ELISA-based Microneutralization Test with Hemagglutination Inhibition Test to Evaluate Neutralizing Antibody against Influenza Virus (H1N1).
P2860
Q27007483-6C0CCF6C-84B3-42B1-AB2C-79867C758466Q28740919-7FA90636-3476-47E2-B311-5242324A8B6AQ30354634-B36E2641-95AA-4484-93C7-1AAE1267164AQ30362521-2F207730-3044-40D1-9E0C-8B96A4AAAAC8Q30364472-5F070B11-34F8-403D-B201-95B417C6F2F6Q30407911-26E53C68-D537-487E-BD4D-2FF424FE0C8EQ30409595-34E9763B-E42C-4949-BE30-15B88794866DQ30412422-578B9671-2173-4E53-96F1-3E562559865AQ30412595-A07C78F4-A9E2-4343-B765-247CB74A25D6Q30417417-2775C6CC-F62C-4B8E-9033-0A867348C536Q30419842-99B1540E-72A9-42CF-A1CF-452627CEE21FQ30420476-DBCCC443-80B8-47E0-A74D-92DEFF808689Q30420821-2B22AF74-1640-4126-871F-CDBDC30C280BQ35959213-2234BA02-958A-4562-A069-FF4917B38A91Q36447199-F4D11844-D886-436A-84E5-545243EA37EDQ38446730-489DE2C9-9B77-46BF-AB0C-EB5232E889A4Q47114379-9B6CB47C-19D4-4421-9163-2B55575261A0
P2860
Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@ast
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
type
label
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@ast
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
prefLabel
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@ast
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
P2093
P1433
P1476
Immunogenicity and tolerabilit ...... e, in HIV-1-infected patients.
@en
P2093
Claude Fortin
Cécile L Tremblay
Danielle Rouleau
Guy Boivin
John Sampalis
Lydie Trautman
Mariana Baz
Mohamed Sylla
P304
P356
10.1016/J.VACCINE.2010.12.023
P407
P577
2010-12-23T00:00:00Z